Recent Advances in Sodium Glucose Cotransporter-2 Inhibitors
10.4093/jkd.2021.22.2.113
- Author:
Dong Hyeok CHO
1
Author Information
1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea
- Publication Type:Focused Issue
- From:Journal of Korean Diabetes
2021;22(2):113-125
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sodium glucose cotransporter-2 inhibitors (SGLT2i) block SGLT2 in the renal proximal tubule and increase the excretion of glucose into the urine, thereby decreasing serum glucose concentrations. These glucose-lowering effects are independent of insulin action. SGLT2i has been demonstrated to reduce cardiovascular complications and hospitalization for heart failure. SGLT2i has also shown remarkable inhibition effects on the progression of renal complications, decreasing serum creatinine, reducing albuminuria, and decreasing death from renal disease. These cardiorenal protective effects appear to be independent of glycemic control efficacy, and in view of these results, SGLT2i is recommended in type 2 diabetes patients at high risk of cardiovascular or renal disease. This review aims to provide an update on the mechanisms, efficacy, cardiorenal protective effects, and adverse effects of SGLT2i.
